Physician profile
Christopher A Michaeles
NPI 1225060684
$3,105.98
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.94 · 2021: $15.39 · 2022: $2,695 · 2023: $239 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,340.81 | 2021-2024 | Cobalt Dr Mri Surescan |
| Edwards Lifesciences Corporation | $1,260.70 | 2022 | |
| Boston Scientific Corporation | $143.76 | 2023-2024 | |
| Abiomed | $140.74 | 2022 | |
| Abbott Laboratories | $77.88 | 2023 | Navitor, Amplatzer Amulet |
| Kestra Medical Technology Services, INC. | $35.70 | 2023 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $33.61 | 2023 | Definity |
| Impulse Dynamics (USA) INC. | $21.56 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $18.44 | 2024 | Farxiga |
| Pfizer INC. | $17.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$350,006.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Michaeles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.